REFERENCES

1. Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, et al. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ 2012;19:428-39.

2. Garvalov BK, Acker T. Cancer stem cells: a new framework for the design of tumor therapies. J Mol Med (Berl) 2011;89:95-107.

3. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014;26:605-22.

4. Mpekris F, Baish JW, Stylianopoulos T, Jain RK. Role of vascular normalization in benefit from metronomic chemotherapy. Proc Natl Acad Sci U S A 2017;114:1994-9.

5. Kaelin WG Jr. The VHL tumor suppressor gene: insights into oxygen sensing and cancer. Trans Am Clin Climatol Assoc 2017;128:298-307.

6. Colwell N, Larion M, Giles AJ, Seldomridge AN, Sizdahkhani S, et al. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro Oncol 2017;19:887-96.

7. Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, et al. Hypoxia-inducible factor 2alpha: a novel target in gliomas. Future Med Chem 2018;10:2227-36.

8. Pietras A, Johnsson AS, Pahlman S. The HIF-2alpha-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. Curr Top Microbiol Immunol 2010;345:1-20.

9. Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, et al. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol 2011;103:43-58.

10. Lofstedt T, Fredlund E, Holmquist-Mengelbier L, Pietras A, Ovenberger M, et al. Hypoxia inducible factor-2alpha in cancer. Cell Cycle 2007;6:919-26.

11. Koh MY, Powis G. Passing the baton: the HIF switch. Trends Biochem Sci 2012;37:364-72.

12. Wu A, Wei J, Kong LY, Wang Y, Priebe W, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 2010;12:1113-25.

13. Eubank TD, Roda JM, Liu H, O’Neil T, Marsh CB. Opposing roles for HIF-1alpha and HIF-2alpha in the regulation of angiogenesis by mononuclear phagocytes. Blood 2011;117:323-32.

14. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002;7:177-89.

15. Wang Q, He Z, Huang M, Liu T, Wang Y, et al. Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2alpha. Nat Commun 2018;9:559.

16. Johannessen TC, Bjerkvig R. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther 2012;12:635-42.

17. Gedye C, Ailles L. Isolation and characterization of cancer stem cells in vitro. Methods Mol Biol 2013;946:181-204.

18. Nusblat LM, Carroll MJ, Roth CM. Crosstalk between M2 macrophages and glioma stem cells. Cell Oncol (Dordr) 2017;40:471-82.

19. Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH, et al. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 2008;265:124-34.

20. Visnyei K, Onodera H, Damoiseaux R, Saigusa K, Petrosyan S, et al. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol Cancer Ther 2011;10:1818-28.

21. Elstner A, Holtkamp N, von Deimling A. Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. Clin Exp Metastasis 2007;24:57-66.

22. Lu H, Li Y, Shu M, Tang J, Huang Y, et al. Hypoxia-inducible factor-1alpha blocks differentiation of malignant gliomas. FEBS J 2009;276:7291-304.

23. Gu L, Nusblat LM, Tishbi N, Noble SC, Pinson CM, et al. Cationic amphiphilic macromolecule (CAM)-lipid complexes for efficient siRNA gene silencing. J Control Release 2014;184:28-35.

24. Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Mol Cancer 2011;10:128.

25. Qiu ZK, Shen D, Chen YS, Yang QY, Guo CC, et al. Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells. Chin J Cancer 2014;33:115-22.

26. Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich JN. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem 2009;284:16705-9.

27. Sparks SM, Waite CL, Harmon AM, Nusblat LM, Roth CM, et al. Efficient intracellular siRNA delivery by ethyleneimine-modified amphiphilic macromolecules. Macromol Biosci 2011;11:1192-200.

28. Sun X, Liu C, Liu D, Li P, Zhang N. Novel biomimetic vectors with endosomal-escape agent enhancing gene transfection efficiency. Int J Pharm 2012;425:62-72.

29. Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, et al. Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner. Cancer Metab 2018;6:3.

30. Méndez O, Zavadil J, Esencay M, Lukyanov Y, Santovasi D, et al. Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer 2010;9:133.

31. Bache M, Rot S, Kessler J, Guttler A, Wichmann H, et al. mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma. Oncol Rep 2015;33:3155-61.

32. Lee G, Auffinger B, Guo D, Hasan T, Deheeger M, et al. Dedifferentiation of glioma cells to glioma stem-like cells by therapeutic stress-induced HIF signaling in the recurrent GBM model. Mol Cancer Ther 2016;15:3064-76.

33. Luwor R, Morokoff AP, Amiridis S, D’Abaco G, Paradiso L, et al. Targeting glioma stem cells by functional inhibition of dynamin 2: a novel treatment strategy for glioblastoma. Cancer Invest 2019;37:144-55.

34. Sun T, Patil R, Galstyan A, Klymyshyn D, Ding H, et al. Blockade of a laminin-411-notch axis with CRISPR/Cas9 or a nanobioconjugate inhibits glioblastoma growth through tumor-microenvironment cross-talk. Cancer Res 2019;79:1239-51.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/